|
STAAR Surgical have announced the FDA approval of EVO and EVO+ Visian Implantable Collamer Lenses, which aim to correct myopia and myopia with astigmatism. It is estimated that more than 2.5 billion people worldwide are affected by myopia, making this a welcome development. "Following FDA approval, prospective patients in the U.S. and their doctors may now consider EVO for achieving Visual Freedom from the limitations, ongoing maintenance and inconvenience associated with glasses and contact lenses,” Caren Mason, CEO and President of Staar Surgical. EVO lenses have already been implanted outside of the US, with over 99.4% of patients saying that they would do the procedure again. In 2021, sales of the lens went up 51%, showing the confidence consumers have in this treatment. “[This] announcement is especially important because the prevalence of myopia is increasing quickly, and COVID precautions have presented additional challenges to people wearing glasses and/or contact lenses" Scott Barnes, Chief Medical Officer of Staar Surgical. This is an exciting and promising development for patients suffering from myopia. 
0 Comments
Johnson & Johnson Vision have received FDA Approval for Acuvue Theravision with Ketotifen – the first drug-eluting contact lens. Each lens will contain a 19mcg of the antihistamine ketotifen. They will be daily disposable contact lenses which aim to prevent ocular itch due to allergic conjunctivitis, whilst also providing vision correctness. These will be available for patients who do not have red eyes, who are suitable for contact lenses and do not have more than 1.00D of astigmatism. “Ocular allergic itch in contact lens wearers may soon be an issue of the past thanks to the decision of the FDA in approving Acuvue Theravision with Ketotifen,” Brian Pall, Director of Clinical Science, Johnson & Johnson. This announcement comes following a positive phase 3 clinical study which ‘showed a clinically and statistically meaningful reduction in itchy allergy eyes as quickly as 3 minutes after lens insertion and lasting up to 12 hours’. The lenses may be worn for longer for vision correction. This new drug eluting technology could have many other applications and we are looking forward to seeing if J&J continue their research in this field and perhaps combine the contact lens with dry eye and other ocular disease medication.  Vision Executives is nearing the end of its first year in business and it has certainly been a rollercoaster of a journey but as my business grows over the next few years I want to share some of our success stories and the people behind them. Without doubt one of the major factors in our success has been bringing on board our marketing & content officer Rachel Glaves. Within a few months of starting with us our article 'Ophthalmology's Advanced Pipeline', which Rachel co-created, was published in The Ophthalmologist . This is a huge achievement for someone who is new to the #eyecare industry and meanwhile is completing her 2nd masters degree! This isn't the first time Rachel has been published either as she has years of freelance journalism experience. Following the completion of her degree, we look forward to Rachel taking on a more strategic role in our team, so if any companies in #ophthalmology would like to collaborate on some content please reach out to Rachel or myself. |
AuthorJames Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news. Archives
December 2022
Categories |
RSS Feed
|
Location |
|
Vision Executives Ltd is a company registered in England & Wales. Company Number 13319387.
Copyright © 2021 Vision Executives Ltd.
Click here to see our privacy policy.
Copyright © 2021 Vision Executives Ltd.
Click here to see our privacy policy.